microRNA-146a: A Biomarker for Epileptogenesis, Epilepsy Prognosis, and Treatment Resistance

  • Dent Z
  • Chen L
1Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Recently, more attention has been paid to identifying biomarkers for epilepsy to direct a more personalized treatment strategy, especially for patients who suffer from drug-resistant epilepsy which carries a much poorer prognosis. microRNA has emerged as an important and diverse type of biomarker that can participate in metabolic and cellular processes of the disease and, importantly, can be detected in patient’s serum. In this short review, we compile state-of-the-art evidence regarding miRNA-146a, a novel biomarker that shows high potential for studying epileptogenesis, monitoring disease progression, evaluating treatment response, and may even function as a therapeutic target given its role in the process of neuroinflammation.

Cite

CITATION STYLE

APA

Dent, Z. O., & Chen, L. (2022). microRNA-146a: A Biomarker for Epileptogenesis, Epilepsy Prognosis, and Treatment Resistance. The Open Biomarkers Journal, 13(1). https://doi.org/10.2174/18753183-v12-e221226-2022-11

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free